信达生物（1801.HK）：礼来战略合作进一步提升公司国际化前景

Investment Rating - The report maintains a "Buy" rating for the company and raises the target price to HKD 110, indicating a potential upside of 23% from the current price of HKD 89.7 [1][10]. Core Insights - The strategic collaboration with Eli Lilly enhances the company's international prospects, marking a significant positive surprise that led to a 12%+ increase in stock price following the announcement. This partnership focuses on the global development of innovative drugs in oncology and immunology, with the company retaining rights in Greater China while Eli Lilly gains exclusive rights outside this region [7]. - The company has established itself as a leader in various business development (BD) transaction models, successfully executing four types of BD transactions, which include co-cooperation and strategic partnerships. This diversification reflects strong market confidence in the company's research and clinical capabilities [7]. - The company anticipates strong commercial performance, projecting product sales of RMB 11.9 billion in 2025, a 45% year-over-year increase, and reiterates a target of RMB 20 billion in product revenue by 2027, primarily driven by innovative drugs [7]. Financial Projections - Revenue is projected to grow significantly, with estimates of RMB 13.4 billion in 2025, RMB 18.8 billion in 2026, and RMB 20 billion in 2027, reflecting year-over-year growth rates of 42.5%, 40.2%, and 6.3% respectively [9]. - The adjusted net profit is expected to reach RMB 1.1 billion in 2025, RMB 4.5 billion in 2026, and RMB 3 billion in 2027, indicating a strong recovery and profitability trajectory [9][11]. - The report highlights a robust gross margin, projected to be 86% in 2025, and a net profit margin of 8.1% in 2025, improving to 23.8% in 2026 [12].